Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men.
Standard
Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men. / Gallina, Andrea; Karakiewicz, Pierre I; Hutterer, Georg C; Chun, Felix; Briganti, Alberto; Walz, Jochen; Antebi, Elie; Shariat, Shahrokh F; Suardi, Nazareno; Graefen, Markus; Erbersdobler, Andreas; Salonia, Andrea; Rigatti, Patrizio; Huland, Hartwig; Montorsi, Francesco.
In: INT J CANCER, Vol. 121, No. 4, 4, 2007, p. 791-795.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men.
AU - Gallina, Andrea
AU - Karakiewicz, Pierre I
AU - Hutterer, Georg C
AU - Chun, Felix
AU - Briganti, Alberto
AU - Walz, Jochen
AU - Antebi, Elie
AU - Shariat, Shahrokh F
AU - Suardi, Nazareno
AU - Graefen, Markus
AU - Erbersdobler, Andreas
AU - Salonia, Andrea
AU - Rigatti, Patrizio
AU - Huland, Hartwig
AU - Montorsi, Francesco
PY - 2007
Y1 - 2007
N2 - Many investigators suggested that obesity predisposes to adverse prostate cancer characteristics and outcomes. We tested the effect of obesity on the rate of aggressive prostate cancer at either prostate biopsy or radical prostatectomy (RP). Clinical and pathological data were available for 1,814 men. Univariable and multivariable logistic regression models addressed the rate of high grade prostate cancer (HGPCa) at either biopsy or final pathology. Clinical stage, prostate-specific antigen (PSA), percentage of free PSA and prostate volume were the base predictors. All models were fitted with and without body mass index (BMI), which quantified obesity. BMI and its reciprocal (InvBMI) were coded as cubic splines to allow nonlinear effects. Predictive accuracy (PA) was quantified with area under curve estimates, which were subjected to 200 bootstrap re-samples to reduce overfit bias. Gains in PA related to the inclusion of BMI were compared using the Mantel-Haenszel test. HGPCa at biopsy was detected in 562 (31%) and HGPCa at RP pathology was present in 931 (51.3%) men. In either univariable or multivariable models predicting HGPCa at biopsy, BMI or InvBMI failed to respectively reach statistical significance or add to multivariable PA (BMI gain = 0%, p = 1.0; InvBMI gain = -0.2%, p = 0.9). Conversely, in models predicting HGPCa at RP, BMI and InvBMI represented independent predictors but failed to increase PA (BMI gain = 0.7%, p = 0.6; InvBMI gain = 0.5, p = 0.7%). Obesity does not predispose to more aggressive prostate cancer at biopsy. Similarly, obesity does not change the ability to identify those who may harbor HGPCa at RP.
AB - Many investigators suggested that obesity predisposes to adverse prostate cancer characteristics and outcomes. We tested the effect of obesity on the rate of aggressive prostate cancer at either prostate biopsy or radical prostatectomy (RP). Clinical and pathological data were available for 1,814 men. Univariable and multivariable logistic regression models addressed the rate of high grade prostate cancer (HGPCa) at either biopsy or final pathology. Clinical stage, prostate-specific antigen (PSA), percentage of free PSA and prostate volume were the base predictors. All models were fitted with and without body mass index (BMI), which quantified obesity. BMI and its reciprocal (InvBMI) were coded as cubic splines to allow nonlinear effects. Predictive accuracy (PA) was quantified with area under curve estimates, which were subjected to 200 bootstrap re-samples to reduce overfit bias. Gains in PA related to the inclusion of BMI were compared using the Mantel-Haenszel test. HGPCa at biopsy was detected in 562 (31%) and HGPCa at RP pathology was present in 931 (51.3%) men. In either univariable or multivariable models predicting HGPCa at biopsy, BMI or InvBMI failed to respectively reach statistical significance or add to multivariable PA (BMI gain = 0%, p = 1.0; InvBMI gain = -0.2%, p = 0.9). Conversely, in models predicting HGPCa at RP, BMI and InvBMI represented independent predictors but failed to increase PA (BMI gain = 0.7%, p = 0.6; InvBMI gain = 0.5, p = 0.7%). Obesity does not predispose to more aggressive prostate cancer at biopsy. Similarly, obesity does not change the ability to identify those who may harbor HGPCa at RP.
M3 - SCORING: Zeitschriftenaufsatz
VL - 121
SP - 791
EP - 795
JO - INT J CANCER
JF - INT J CANCER
SN - 0020-7136
IS - 4
M1 - 4
ER -